Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
22.27
-2.31 (-9.40%)
At close: Apr 23, 2026, 4:00 PM EDT
22.43
+0.16 (0.72%)
After-hours: Apr 23, 2026, 7:55 PM EDT
Summit Therapeutics Stock Forecast
Stock Price Forecast
The 15 analysts that cover Summit Therapeutics stock have a consensus rating of "Buy" and an average price target of $32.93, which forecasts a 47.87% increase in the stock price over the next year. The lowest target is $12 and the highest is $45.
Price Target: $32.93 (+47.87%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Summit Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 8 | 7 | 7 | 7 | 8 |
| Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Hold | 2 | 3 | 3 | 3 | 4 | 4 |
| Sell | 2 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 16 | 15 | 15 | 16 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +102.07% | Apr 8, 2026 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $42 → $15 | Strong Buy → Hold | Downgrades | $42 → $15 | -32.64% | Mar 16, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $30 | Strong Buy | Maintains | $40 → $30 | +34.71% | Feb 24, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +79.61% | Feb 2, 2026 |
| Citizens | Citizens | Buy Reiterates $40 | Buy | Reiterates | $40 | +79.61% | Jan 30, 2026 |
Financial Forecast
Revenue This Year
8.53M
Revenue Next Year
105.96M
from 8.53M
Increased by 1,142.50%
EPS This Year
-1.07
from -1.44
EPS Next Year
-1.10
from -1.07
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 61.0M | 377.9M | ||||||
| Avg | 8.5M | 106.0M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 4,330.9% | ||||||
| Avg | - | 1,142.5% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.60 | -0.61 | ||||||
| Avg | -1.07 | -1.10 | ||||||
| Low | -1.62 | -1.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.